South Korea's leading pharmaceutical companies each invested around 100 billion won (approximately $72.13 million) in research and development during the first half of 2026, according to regulatory filings released on 23 August. The surge in R&D spending reflects a sector-wide drive to build new drug pipelines and secure long-term growth as global competition in biopharmaceuticals intensifies.

Key R&D Figures Across Major Firms

Yuhan Corp., widely recognised for its anti-inflammatory ointment Antiphlamine, committed 122.2 billion won to R&D in the January–June period — a 13.8 percent increase over the same period last year, according to its regulatory filing. The outlay represented 10.5 percent of the company's first-half sales.

Chong Kun Dang Pharmaceutical Corp., known for the household pain reliever Penzal, allocated 113.5 billion won — or 12.3 percent of its first-half revenue — to new drug development. That figure marks a sharp 36.6 percent jump compared with its R&D expenditure in the first half of 2025, per the company's regulatory disclosure.

Hanmi Pharm Co. spent 125.5 billion won, equivalent to 14.6 percent of its half-year sales, on R&D. According to a company official, Hanmi Pharm launched an initiative in 2023 to develop a new pipeline of obesity drugs — a segment that has attracted fierce global investment.

Mid-Tier Companies Follow Suit

The trend extended well beyond the industry's top names. Mid-sized firms also directed roughly 10 percent of their first-half revenue into new drug development. GC Biopharm Co. reported R&D spending of 85.9 billion won, while Daewoong Pharma invested 115.7 billion won over the same period. This broad-based commitment signals that the R&D push is a structural shift rather than an outlier strategy among a handful of large players.

Biopharmaceutical Exports on Record Pace

The domestic R&D momentum comes alongside a strong export performance. South Korea's biopharmaceutical exports reached an estimated $4.5 billion in the first half of this year, up 15.3 percent, according to data from the Ministry of Food and Drug Safety. That figure accounted for 86.5 percent of total pharmaceutical exports of $5.2 billion in the same period.

Biopharmaceutical exports have climbed steadily — from $4.9 billion in 2023 to $7.6 billion in 2025. Should the current trajectory hold, the ministry expects full-year 2026 exports to set a new all-time record. This comes amid rising global demand for biologics, biosimilars, and obesity therapeutics — areas where several Korean firms are actively building pipelines.

What This Signals for the Sector

The collective R&D intensity — with multiple companies dedicating over 12 percent of revenue to drug development — places South Korea's pharmaceutical sector among the more aggressive innovators in Asia. Notably, the focus on obesity drugs by firms such as Hanmi Pharm mirrors a global race triggered by the commercial success of GLP-1 class treatments. With export records potentially within reach and domestic pipelines expanding, South Korea's pharma industry appears to be positioning itself for a significant leap in global market share over the next several years.